Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GALK1 | P51570 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.53 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237211 | 1.00 | MAOB (0.65) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL12812271 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL3636327 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL8818263 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL8843011 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL7998325 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL3636329 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL4453793 | 0.95 | MAOB (0.70) | MAOBSYNJ2KDM4EABL1ALPL | |
| SCHEMBL29556480 | 0.87 | MAOB (0.51) | MAOBKDM4EPOLBGAAMAPT | |
| SCHEMBL1239253 | 0.86 | SLC6A2 (0.56) | MAOBSYNJ2KDM4EABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956039-B2 | Use of amygdalin analogues for the treatment of psoriasis | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2011-06-07 | — | — | US | claimed |
| US-20110028410-A9 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2011-02-03 | — | — | US | claimed |
| EP-1847270-B1 | USE OF AMYGDALIN ANALOGUES FOR THE TREATMENT OF PSORIASIS | UNIV CATALUNYA POLITECNICA (ES) | 2010-03-03 | — | — | EP | claimed |
| US-20080125378-A1 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2008-05-29 | — | — | US | claimed |
| EP-1847270-A1 | USE OF AMYGDALIN ANALOGUES FOR THE TREATMENT OF PSORIASIS | Universitat Politecnica de Catalunya (ES) | 2007-10-24 | — | — | EP | claimed |
| US-7956039-B2 | Use of amygdalin analogues for the treatment of psoriasis | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2011-06-07 | — | — | US | disclosed |
| US-20110028410-A9 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2011-02-03 | — | — | US | disclosed |
| EP-1847270-B1 | USE OF AMYGDALIN ANALOGUES FOR THE TREATMENT OF PSORIASIS | UNIV CATALUNYA POLITECNICA (ES) | 2010-03-03 | — | — | EP | disclosed |
| US-20080125378-A1 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2008-05-29 | — | — | US | disclosed |
| EP-1847270-A1 | USE OF AMYGDALIN ANALOGUES FOR THE TREATMENT OF PSORIASIS | Universitat Politecnica de Catalunya (ES) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028410-A9 | Use of Amygdalin Analogues for the Treatment of Psoriasis | C3AR1, CCR7, C5AR1 | MAOB 776/4885SYNJ2 4699/4885KDM4E 4693/4885 |
| US-20080125378-A1 | Use of Amygdalin Analogues for the Treatment of Psoriasis | C3AR1, CCR7, C5AR1 | MAOB 776/4885SYNJ2 4699/4885KDM4E 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.